[Tenoxicam in treatment of oral inflammation and pain]

The efficacy of a new nonsteroidal anti-inflammatory agent, Tenoxicam, was valued in a study of 58 patients distinguished into 3 groups, group A consist of 29 patients with inflammatory diseases of the mouth, group 1B and 2B (29 patients) with acute postoperative pain. Drug was given at doses of: 1) 20 mg/die in group A; 2) 40 mg/die for the first two days and 20 mg/die for successive days in group 1B; 3) 20 mg/die in group 2B, for a period variable from 5 to 7 days. The outcomes showed that the administration of Tenoxicam resulted in a effective reduction of all inflammatory valued parameters (fever in 100%, inflammatory pain in 94% and edema in 90% of all cases) for the group A: acute postoperative pain was significantly reduced in group 1B where the patients have assumed drug at dose of 40 mg/die for the first two days and 20 mg/die for successive days. In group 2B (20 mg/die) drug's smaller dose showed reduced efficacy for control of postoperative pain. Although Tenoxicam was well tolerated and mild side effects were recorded only in 5% of cases.